The use of Liraglutide, a Glucagon-like peptide 1 (GLP-1) analog, has been approved by the European Medicines Agency (EMA) for treating obesity in children aged 12 years or older. This evidence concerns the gene GLP1R and obesity due to melanocortin 4 receptor deficiency.